Schedule your first visit and labs → Schedule Online

Benefits vs Risks of Bioidentical Hormone Replacement Therapy

Benefits vs Risks of Bioidentical Hormone Replacement Therapy Doctor Seattle & Bellevue

References

  1. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Agnès Fournier, Franco Berrino, and Françoise Clavel-Chapelon. Breast Cancer Res Treat. 2008 January; 107(1): 103–111.
  2. Effects of Progesterone on Sleep: A Possible Pharmacological Treatment for Sleep-Breathing Disorders? Andersen, M. L.; A. Bittencourt, L. R.; Antunes, I. B.; Tufik, S. Source: Current Medicinal Chemistry, Volume 13, Number 29, December 2006 , pp. 3575-3582(8).
  3. Effects of topical estradiol on the facial skin collagen of postmenopausal women under oral hormone therapy: a pilot study. Patriarca MT, Goldman KZ, Dos Santos JM, Petri V, Simões RS, Soares JM Jr, Simões MJ, Baracat EC. Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):202-5. Epub 2006 Jun 23.
  4. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. L’hermite M, Simoncini T, Fuller S, Genazzani AR. Maturitas. 2008 Jul-Aug;60(3-4):185-201. doi: 10.1016/j.maturitas.2008.07.007. Epub 2008 Sep 5.
  5. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Davis SR, Braunstein GD. J Sex Med. 2012 Apr;9(4):1134-48. doi: 10.1111/j.1743-6109.2011.02634.x. Epub 2012 Feb 3.
  6. Carmichael MS, Warburton VL, Dixen J, Davidson JM. Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Arch Sex Behav 1994;23(1):59-79.
  7. Carmichael MS, Warburton VL, Dixen J, Davidson JM. Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Arch Sex Behav 1994;23(1):59-79.
  8. Amico JA, Seif SM, Robinson AG. Oxytocin in human plasma: correlation with neurophysin and stimulation with estrogen. J Clin Endocrinol Metab 1981;52(5):988-993.
  9. Kalin NH, Gibbs DM, Barkskdale CM, Shelton SE, Carnes M. Behavorial Stress Decreases Plasma Oxytocin Concentrations in Primates. Life Sciences 1985;36:1267-1280.
  10. Argiolas A, Gessa GL, Melis MR, Stancampiano R, VACCARI A. Effects of Neonatal and Adult Thyroid Dysfunction on Thymic Oxytocin. Neuroendocrinology 1990;52:556-559.
  11. Evans JJ. Oxytocin in the human–regulation of derivations and destinations. Eur J Endocrinol 1997;137(6):559-571.
  12. Purba JS, Hofman MA, Portegies P, Troost D, Swaab DF. Decreased Number of Oxytocin Neurons in the Paraventricular Nucleus of the Human Hypothalamus in AIDS. Brain 1993;116:795-809.
  13. Oxytocin could be new social-phobic treatment. Health News 2006;12(3):10-11.
  14. Moller A, Hansen BL, Hansen GN, Hagen C. Autoantibodies in sera from patients with multiple sclerosis directed against antigenic determinants in pituitary growth hormone-producing cells and in structures containing vasopressin/oxytocin. J Neuroimmunol 1985;8(2-3):177-184.
  15. Anderberg UM, Uvnas-Moberg K. Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000;59(6):373-379.
  16. Evans JJ. Oxytocin in the human–regulation of derivations and destinations. Eur J Endocrinol 1997;137(6):559-571.
  17. van Wimersma Greidanus TB, van de Heijning BJ. Opioid control of vasopressin and oxytocin release. Regul Pept 1993;45(1-2):183-186.
  18. Martin A, State M, Anderson GM et al. Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report. Biol Psychiatry 1998;44(12):1349-1352.
  19. Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997;423:50-54.
  20. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995;80(2):573-579.
  21. Lucht MJ, Barnow S, Sonnenfeld C et al. Associations between the oxytocin receptor gene (OXTR) and affect, loneliness and intelligence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(5):860-866.
  22. Scantamburlo G, Hansenne M, Fuchs S et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007;32(4):407-410.
  23. Goldman M, Marlow-O’Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 2008;98(1-3):247-255.
  24. Panksepp J. Commentary on the Possible Role of Oxytocin in Autism. Journal of Autism and Developmental Disorders 1993;23(3):567-569.
  25. Elevated Salivary Levels of Oxytocin Persist More than 7 h after Intranasal Administration. van Ijzendoorn MH, Bhandari R, van der Veen R, Grewen KM, Bakermans-Kranenburg MJ. Front Neurosci. 2012;6:174. doi: 10.3389/fnins.2012.00174. Epub 2012 Dec 7.
  26. Effects of Oxytocin Outside Pregnancy. Lippert TH, Mueck AO, Seeger H, Pfaff A. Horm Res 2003;60:262–271 (DOI: 10.1159/000074243)
  27. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Nat Rev Neurosci. 2011 Aug 19;12(9):524-38. doi: 10.1038/nrn3044.
  28. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Van IJzendoorn MH, Bakermans-Kranenburg MJ. Psychoneuroendocrinology. 2012 Mar;37(3):438-43. doi: 10.1016/j.psyneuen.2011.07.008. Epub 2011 Jul 29.
  29. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23.
  30. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Biol Psychiatry. 2003 Dec 15;54(12):1389-98.
  31. Intranasal oxytocin attenuates the cortisol response to physical stress: A dose-response study. Cardoso C, Ellenbogen MA, Orlando MA, Bacon SL, Joober R. Psychoneuroendocrinology. 2013 Mar;38(3):399-407. doi: 10.1016/j.psyneuen.2012.07.013. Epub 2012 Aug 11.
  32. TSH may not be a good marker for adequate thyroid hormone replacement therapy. Alevizaki M, Mantzou E, Cimponeriu AT, Alevizaki CC, Koutras DA. Wien Klin Wochenschr. 2005 Sep;117(18):636-40.
  33. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V, Skarulis MC, Kozlosky M, Csako G, Costello R, Pucino F. J Clin Endocrinol Metab. 2011 Nov;96(11):3466-74. doi: 10.1210/jc.2011-1329. Epub 2011 Aug 24.
  34. Thyroid Disorders in Elderly Patients Shakaib U. Rehman MD, Dennis W. Cope MD, Anna D. Senseney MD, Walter Brzezinski MD. http://www.medscape.com/viewarticle/504978_5 (last accessed on 4/8/13). Southern Medical Journal
  35. Altered intestinal absorption of L-thyroxine caused by coffee. Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, Saraceno G, Trimarchi F. Thyroid. 2008 Mar;18(3):293-301. doi: 10.1089/thy.2007.0222.
  36. Abnormal circadian rhythm and cortisol excretion in autistic children: a clinical study. Lakshmi Priya MD, Geetha A, Suganya V, Sujatha S. Croat Med J. 2013 Feb 15;54(1):33-41.
  37. Aging, health behaviors, and the diurnal rhythm and awakening response of salivary cortisol. Heaney JL, Phillips AC, Carroll D. Exp Aging Res. 2012;38(3):295-314. doi: 10.1080/0361073X.2012.672134.
  38. Comparison of salivary versus serum testosterone levels in postmenopausal women receiving transdermal testosterone supplementation versus placebo. Flyckt RL, Liu J, Frasure H, Wekselman K, Buch A, Kingsberg SA. Menopause. 2009 Jul-Aug;16(4):680-8. doi: 10.1097/gme.0b013e318199d5c4.
  39. Salivary steroid assays – research or routine? Wood P. Ann Clin Biochem. 2009 May;46(Pt 3):183-96. doi: 10.1258/acb.2008.008208. Epub 2009 Jan 28.
  40. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Heim C, Ehlert U, Hellhammer DH. Psychoneuroendocrinology. 2000 Jan;25(1):1-35.
  41. Stress-induced hypocortisolemia diagnosed as psychiatric disorders responsive to hydrocortisone replacement. Schuder SE. Ann N Y Acad Sci. 2005 Dec;1057:466-78.
  42. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. Maguire AM, Ambler GR, Moore B, McLean M, Falleti MG, Cowell CT. Pediatrics. 2007 Jul;120(1):e164-71. Epub 2007 Jun 18.
  43. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Phytomedicine. 2000 Dec;7(6):463-9.
  44. Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Panossian A, Wagner H. Phytother Res. 2005 Oct;19(10):819-38.
  45. Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women. Gómez-Santos C, Hernández-Morante JJ, Tébar FJ, Granero E, Garaulet M. Clin Endocrinol (Oxf). 2012 Oct;77(4):548-54. doi: 10.1111/j.1365-2265.2011.04306.x.

Pages: 1 2

{ 0 comments… add one now }

Leave a Comment

Previous post: